Maxygen Aps

Maxygen, Inc.

Poul Baad Rasmussen

Kim Vilbour Andersen

Claus Bornaes

Grethe Norskov Rasmussen

Anders Pedersen

The invention relates to a conjugate exhibiting interferon &#x3b2; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Interferon beta-like molecules

The present invention provides new interferon &#x3b2; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.

Interferon-&#x3b2; variants and conjugates

Interferon &#x3b2; variants and conjugates

Growing community of inventors

Soeberg, Denmark

Poul Baad Rasmussen